<DOC>
	<DOCNO>NCT00279565</DOCNO>
	<brief_summary>This randomize , single-center , control study design evaluate safety , tolerability , efficacy treatment Peg-Intron Rebetol methadone buprenorphine maintenance patient hepatitis C .</brief_summary>
	<brief_title>Buprenorphine Versus Methadone Maintenance Hepatitis C Patients Receiving Peg-Intron Rebetol ( Study P04279 ) ( TERMINATED )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>Male female patient history intravenous drug abuse , willing undergo methadone buprenorphine substitution . Patients newly diagnose chronic hepatitis C. Age 1865 . Hepatitis C virus ( HCV ) ribonucleic acid ( RNA ) positive serum measure polymerase chain reaction ( PCR ) within last 4 week . Genotype 2 3 . Elevated alanine aminotransferase ( ALT ) level . In woman childbearing age , pregnancy must exclude prior entry study , use safe contraceptive device ( intrauterine device , oral contraceptive , diaphragm + spermicide , condom + spermicide , tubal ligation ) must document . Lab parameter : Hemoglobin : &gt; =12 g/dL ( woman ) &gt; =13 g/dL ( men ) Leukocytes &gt; =3,000/µL Thrombocytes &gt; =100,000/µL Prothrombin time ( PT ) /partial thromboplastin time ( PTT ) /coagulation within normal range Albumin : 10 % deviation low normal value Thyroidstimulating hormone ( TSH ) normal Creatinine normal Uric acid normal Antinuclear antibody &lt; =1:160 Signed informed consent . Refusal woman childbearing age sexually active patient use safe contraceptive . Breastfeeding woman . Cirrhosis stage B C accord ChildPugh . Signs decompensated liver disease ( ascites , bleed varix spontaneous encephalopathy ) . Confirmed coinfection human immunodeficiency virus ( HIV ) hepatitis B virus ( HBV ) . Existing psychiatric comorbidity . Alcohol abuse . Active malignant disease suspicion history malignant disease within five previous year ( except adequately treat basal cell carcinoma ) . Existing psoriasis dermatological disorder ( relative exclusion criterion : due great difference regard severity disorder individual therapy compatibility , therapy decision discretion physician ) . Treatment study drug within last 30 day . Any uncontrolled underlying medical condition ( e.g . diabetes ) . Clinically significant electrocardiogram ( ECG ) abnormalities / significant cardiovascular dysfunction within last 6 month ( angina , heart failure , recent myocardial infarction , severe hypertension significant arrhythmia ) exclusion criterion . In case suspect heart disease , cardiologic examination require prior inclusion patient . Any liver disorder genesis study indication ( regard elevate iron level , patient manifest hemochromatosis exclude ) . Autoimmune disorder ( except LKMpositive patient : patient may include study ) . Misuse buprenorphine methadone .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>buprenorphine</keyword>
	<keyword>methadone</keyword>
	<keyword>Peg-Intron</keyword>
	<keyword>Rebetol</keyword>
</DOC>